Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
A genomic sequence on paper in a collaborative workspace

Jul 2, 2026

Claude Hackathon Supercharges Life Sciences

Claude has launched the Built with Claude Life Sciences hackathon, aimed at advancing AI applications in the life sciences sector. In partnership with Gladstone Institute, this global virtual event offers a $100,000 prize pool for participants utilizing Claude's specialized tools for research and coding.The hackathon is designed to enhance the integration of AI in life sciences by providing participants with access to Claude Science and Claude Code. These tools facilitate the analysis of biologi
A petri dish with cultured cells in a dim laboratory setting, illuminated by soft ambient light.

Jul 2, 2026

Insilico Medicine and Takeda join to accelerate AI-powered drug discovery

Insilico Medicine has partnered with Takeda to enhance drug discovery through AI technologies, aiming to streamline the development of new therapies.This collaboration will leverage Insilico’s Pharma.AI platform alongside Takeda’s drug development expertise to expedite the identification and advancement of new drug candidates across key therapeutic areas. The partnership focuses on improving the efficiency of early-stage drug discovery while enhancing the probability of developing medicines with
A minimalist illustration of a pill and a light bulb representing AI drug discovery.

Jul 2, 2026

Takeda Invests $600M in Insilico's AI Drug Discovery

Takeda is making a significant move in the realm of AI-driven drug discovery by partnering with Insilico Medicine in a deal potentially worth up to $600 million. This collaboration will leverage Insilico's Pharma.AI platform to identify new drug candidates across Takeda's extensive therapeutic portfolio.The agreement allows Insilico to receive approximately $60 million in upfront and near-term payments, with additional success-based milestones potentially raising the total to $600 million. Taked
A scientist's hand holding a molecular compound in a dimly lit lab.

Jul 2, 2026

Mankind Pharma Partners with Denovo Sciences to Advance AI-Led Drug Discovery

Mankind Pharma has teamed up with Denovo Sciences to enhance drug discovery through artificial intelligence, aiming to streamline the R&D process.This collaboration merges Mankind Pharma's extensive research and clinical development expertise with Denovo Sciences' advanced AI platform, which specializes in molecular generation and prioritization. The partnership adopts a human-in-the-loop approach, allowing AI to generate and assess molecular candidates while scientists refine these candidates t
Minimalist illustration of a molecular structure

Jul 2, 2026

Mankind Pharma, Denovo Sciences Join Forces for AI-Led Drug Discovery

Mankind Pharma has partnered with Denovo Sciences to enhance drug discovery through AI technology, signaling a significant advancement in their commitment to innovation in research and development.This collaboration combines Mankind Pharma’s robust research and development capabilities with Denovo Sciences’ AI-driven molecular generation platform. The partnership employs a human-in-the-loop model, where AI assists in generating and evaluating molecular candidates, while scientific experts provid
A laboratory vial filled with a colorful liquid on a shelf in a dimly lit lab.

Jul 2, 2026

Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discovery

Mankind Pharma and Denovo Sciences are collaborating to enhance drug discovery through artificial intelligence. This partnership focuses on leveraging AI technology to streamline the drug development process. By combining AI capabilities with human expertise, Mankind Pharma and Denovo Sciences aim to reduce the time it takes to bring new drugs to market while simultaneously increasing the quality of candidates. The collaboration seeks to pinpoint the most promising drug options, thus optimizing
A minimalist representation of a drug molecule in flat design.

Jul 2, 2026

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

Insilico Medicine has entered a strategic partnership with Takeda to enhance drug discovery using AI technology.The collaboration focuses on leveraging Insilico's Pharma.AI platform to identify and develop novel drug candidates across Takeda's therapeutic areas. The goal is to utilize advanced generative models from the initial design stages to enhance the quality of drug candidates, ensuring they meet high efficacy and safety standards. Insilico will spearhead the AI-driven discovery process, w
A test tube on a lab bench in a research setting.

Jul 2, 2026

Anthropic debuts AI-driven pharma R&D tool, Claude Science

Anthropic has launched Claude Science, a new AI tool designed to enhance drug discovery workflows by integrating various research tools into a unified platform.This innovative application aims to streamline the fragmented processes in pharmaceutical research, enabling scientists to conduct multi-step studies more efficiently. Available for Linux and macOS, as well as through remote access, Claude Science is currently in beta testing and promises to consolidate resources such as PubMed, Jupyter,
A flat illustration of a drug molecule silhouette on a light gray background.

Jul 2, 2026

Insilico Medicine Partners with Takeda in AI Drug Discovery Deal Worth Up to $600 Million

Insilico Medicine has entered into a significant partnership with Takeda Pharmaceutical, aimed at enhancing drug discovery through AI technology. The collaboration, valued at up to $600 million, will utilize Insilico's generative AI platform to develop innovative drug candidates across various therapeutic areas.The agreement includes an initial payment and milestone payments totaling around $60 million, with the potential for further payments as specific development targets are met. Insilico's P
Minimalist illustration of DNA and molecular structure

Jul 2, 2026

Mankind Pharma and Denovo Sciences join hands to accelerate AI-powered drug discovery

Mankind Pharma has announced a strategic partnership with Denovo Sciences to enhance its drug discovery efforts through artificial intelligence.This collaboration aims to leverage Mankind Pharma’s research and clinical development strengths alongside Denovo Sciences’ advanced AI platform for molecular generation and prioritization. The approach integrates a human-in-the-loop model, where AI assists in generating and assessing molecular candidates, while scientists provide validation and refineme
Petri dish with cell cultures in a dimly lit lab

Jul 2, 2026

Takeda and Insilico ink $600M AI drug discovery agreement

Takeda Pharmaceutical has entered a significant partnership with Insilico Medicine, a biotech firm specializing in AI-driven drug discovery, with a deal potentially worth up to $600 million. This collaboration is part of a broader trend where pharmaceutical companies are increasingly investing in artificial intelligence capabilities to enhance drug development processes.The partnership combines Takeda's extensive pharmaceutical expertise with Insilico's innovative Pharma.AI platform, which utili
A minimalist illustration of a pill representing drug discovery.

Jul 1, 2026

Mankind Pharma partners Denovo Sciences for AI-led drug discovery

Mankind Pharma has joined forces with Denovo Sciences to leverage artificial intelligence in drug discovery, aiming to streamline the research process significantly.This partnership is designed to reduce the time required for early-stage research while improving the quality of drug candidates. By integrating Mankind Pharma's robust research and development capabilities with Denovo's advanced AI technology, the collaboration seeks to prioritize the most promising drug candidates for further devel